Shares of Day One Biopharmaceuticals (NASDAQ: DAWN) have surged over 50% in the last three months, reigniting debate over its fair value and the risks tied to its lead drug OJEMDA and a pivotal upcoming data readout.
Despite posting a quarterly loss in its core wood products unit amid 'extremely challenging' markets, Weyerhaeuser closed 2025 with strategic pivots. The forestry giant is doubling down on its land management and nascent 'Climate Solutions' business, while managing a disciplined capital return to shareholders.
WisdomTree Investments capped off a transformative 2025 with record assets under management, fueled by a landmark European expansion and a burgeoning digital assets platform. The firm's strategic acquisition of Ceres Partners has also opened a new frontier in private markets, setting the stage for continued margin growth in 2026.
Coeur Mining's acquisition of New Gold has received final court approval in British Columbia, marking a pivotal step toward creating a larger, diversified precious metals producer. The deal is poised to reshape the competitive landscape for mid-tier gold and silver miners in North America.
OpenAI is reportedly in late-stage discussions to secure a colossal funding package, potentially nearing $40 billion, from its key partners and suppliers Nvidia, Amazon, and Microsoft, as the AI leader seeks capital for an ambitious global expansion.
Deutsche Bank has upgraded NNN REIT to 'Buy' with a $47 price target, highlighting its defensive portfolio and sustainable dividends as relative strengths in a challenging real estate investment trust environment expected to persist through 2026.
A discounted cash flow analysis suggests Eupe Corporation Berhad (KLSE:EUPE) may be trading close to its intrinsic value. We examine the assumptions behind the numbers and what investors should consider beyond the model.
Future Proof Brands, maker of the popular ready-to-drink brand BeatBox, is laying off over 150 employees at its headquarters. The move comes weeks after announcing a $490 million majority stake acquisition by Anheuser-Busch, signaling corporate restructuring ahead of the deal's expected close in early 2026.
Analyses from multiple artificial intelligence models project divergent paths for Ethereum, Solana, and XRP by 2026, highlighting varying risk-reward profiles based on technological adoption, regulatory landscapes, and market structure.
Deutsche Bank has upgraded AI infrastructure provider CoreWeave to 'Buy,' significantly raising its price target to $140, citing a strong medium-term outlook and capacity expansion plans backed by a deepened partnership with Nvidia.
Ovid Therapeutics (NASDAQ: OVID) has garnered analyst optimism following positive Phase 1 trial results for its novel neurological drug candidate and a recent 'Outperform' initiation. The biotech firm is now shifting focus to a more potent oral therapy, with key regulatory milestones ahead.
Piper Sandler raises its price target for Century Therapeutics (IPSC), highlighting the biotech firm's robust financial position extending into 2029 and an upcoming Investigational New Drug application for its lead cell therapy candidate, CNTY-813.
Citi raises Lexicon Pharmaceuticals' price target to $2.10, citing strong momentum from its collaboration with Novo Nordisk on obesity drug candidate LX9851 and improved financials.
A mixed third-quarter earnings season for therapeutics stocks reveals divergent paths, with United Therapeutics missing estimates while peers like Halozyme and Biogen post strong beats. Sector-wide revenue growth and positive stock reactions suggest underlying investor confidence despite regulatory and pricing headwinds.
Barclays' upgrade of PTC Therapeutics to Overweight has spotlighted the biotech firm's valuation, with shares showing strong momentum but questions lingering over its path to profitability and reliance on a narrow drug portfolio.
While rising crude prices have lifted Occidental Petroleum's stock recently, a mixed earnings performance and a predominantly 'Hold' rating from Wall Street signal lingering skepticism about its near-term trajectory.
Amneal Pharmaceuticals' shares have surged over 64% in the past year, prompting investors to question if the rally still has room to run. A closer look at valuation metrics suggests the generic drugmaker may still be trading at a significant discount to its intrinsic value.
Fermi Inc. is confronting multiple class action lawsuits alleging it misled investors about tenant demand and funding risks for its flagship AI data center project, Project Matador. The legal challenges emerge as the company navigates a high-stakes, capital-intensive build-out in a competitive sector.
Shares of Corcept Therapeutics plunged 16% after a corrected FDA letter disclosed the agency had repeatedly cautioned the company against filing its application for a Cushing's syndrome drug, which was later rejected over efficacy and safety concerns.
The United States, in coordination with European allies, has imposed new sanctions on Iran's Interior Minister and other officials, accusing them of orchestrating a violent suppression of nationwide protests. The measures target assets and travel, reflecting a widening international response to Tehran's handling of domestic unrest.
